Clinical Briefings™: Expanding the Armamentarium in Psoriasis Treatment: Where Do TYK2 Inhibitors Fit Into the Treatment Landscape?

Release Date: November 27, 2019
Expiration Date: November 27, 2020
Media: Internet - based

Activity Overview

Psoriasis is the most common immune-mediated inflammatory disease in the United States, affecting approximately 2% to 3% of the population. No cure exists for this chronic, painful, and disfiguring skin condition with its unpredictable course of symptoms, external triggers, and significant comorbidities that can substantially reduce a patient’s quality of life. In the past decade, significant research has increased the understanding of the pathophysiology of psoriasis, leading to the development of targeted disease-modifying therapies. One of those targets is tyrosine kinase 2 (TYK2), a member of the Janus kinase family. Evidence has demonstrated that TYK2 activity is necessary to signal the interleukin (IL)-12 and IL-23 cytokines, and type I interferons, and that blocking TYK2 activity inhibits the signaling effects of IL-12 and IL-23 to ultimately interrupt cellular processes involved in the formation of psoriatic lesions. Furthermore, capitalizing on the TYK2 activity pathway versus a JAK mechanism may provide novel selective treatment agents for psoriasis and other autoimmune diseases without the hematological adverse effects seen with JAK inhibition.

In this Clinical Briefings™ program, a series of audio interviews with dermatology expert Jashin Wu, MD, will update clinicians on emerging agents for the treatment of psoriasis and provide insights and latest evidence for individualized management of psoriasis.

Benefits of Participating

• Update your knowledge of treat-to-target guidelines that may improve patient outcomes and treatment satisfaction
• Learn new strategies to improve patient adherence to treatment
• Build confidence in managing patients with moderate-to-severe psoriasis by incorporating biologic therapies into treatment plans
• Gain awareness of the pathophysiology behind emerging psoriasis treatments and recent data on their efficacy and safety

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Bristol-Myers Squibb.

Target Audience

This online educational activity is directed toward dermatologists, primary care physicians, nurse practitioners, physician assistants, nurses, and other health care professionals who are involved in the treatment of patients with psoriasis.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Review the etiology, pathophysiology, and diagnostic considerations of psoriasis
• Evaluate the latest data on the efficacy, safety, and dosing administration of novel TYK2 inhibitors for patients with psoriasis
• Examine the potential impact of targeted TYK2 inhibitors on treatment of patients with psoriasis

Faculty, Staff, and Planners’ Disclosures

Faculty

Jashin J. Wu, MD
Founder and CEO, Dermatology Research and Education Foundation
Founder and Course Director
San Diego Dermatology Symposium, May 29-31, 2020
Irvine, CA

Disclosures: Consultant: AbbVie, Almirall, Amgen, Bristol-Myers Squibb, Celgene, Dermira, Dr Reddy’s Laboratories, Eli Lilly, Janssen, LEO Pharma, Novartis, Promius Pharma, Regeneron, Sun Pharmaceutical, UCB, Valeant Pharmaceuticals North America LLC; Speakers Bureau: AbbVie, Celgene, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, UCB, Valeant Pharmaceuticals North America LLC.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, PER^® makes it a policy to ensure fair balance, independence, objectivity, and scientific rigor in all its CME/CE activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the company that provided commercial support.